Stockreport

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting [Yahoo! Finance]

Taysha Gene Therapies, Inc.  (TSHA) 
PDF endpoint of gain/regain of = one natural history defined developmental milestone assessed via video-evidenced review by independent central raters New supplemental ana [Read more]